Evidence map›Paper›PMID 15547079›Full record

ArticleAnnals of the rheumatic diseases2004

Divergent roles of nitrergic and prostanoid pathways in chronic joint inflammation.

S M Day, J C Lockhart, W R Ferrell, J S McLean

Open access · bronzeAbstract read
In one paragraph

Article in Annals of the rheumatic diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins.Proceedings of the National Academy of Sciences of the United States of America · 2011
    Article
  3. Can L(+)-lactate be used as a marker of experimentally induced inflammation in rats?Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2010
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

S M DayBiological Sciences, University of Paisley, Paisley PA1 2BE, Scotland, UK.
J C Lockhart
W R Ferrell
J S McLean
University of the West of Scotland · GBGlasgow Royal Infirmary · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNitrergic and prostanoid pathways have both been implicated in inflammatory processes.

objectiveTo investigate their respective contributions in a rat model of chronic arthritis.

methodsMale Wistar rats (n = 4-6/group) received either an intra-articular injection of 2% carrageenan/4% kaolin (C/K) or intra- and periarticular injections of Freund's complete adjuvant (FCA; 10 mg/ml M tuberculosis). Joint diameter, urinary nitric oxide metabolites (NO(x)), and prostaglandin E(2) (PGE(2)) levels were measured as indices of the inflammatory process. A prophylactic and therapeutic (day 5) dose ranging study of an inducible nitric oxide synthase inhibitor, L-N-(1-iminoethyl)-lysine (L-NIL), and a cyclo-oxygenase-2 (COX-2) inhibitor, SC-236, was performed with the drugs given subcutaneously. Submaximal doses were identified and used for combination studies. Appropriate vehicle controls were included.

resultsL-NIL and SC-236 dose dependently inhibited C/K induced acute joint swelling, the magnitude being greatest when they were given in combination. Both prophylactic and therapeutic administration of SC-236 in the FCA induced model of chronic arthritis produced a dose dependent reduction in all the measures assessed. However, although L-NIL demonstrated similar dose dependent inhibition of urinary NO(x) and PGE(2) levels, joint swelling was significantly exacerbated in this model. Co-administration of the inhibitors nullified the benefits of SC-236.

conclusionWhereas COX-2 derived prostaglandins are proinflammatory in both acute and chronic joint inflammation, NO seems to have divergent roles, being anti-inflammatory in chronic and proinflammatory in acute joint inflammation.

Indexed as

Acute DiseaseAnimalsArthritis, ExperimentalBenzenesulfonamidesCarrageenanChronic DiseaseCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDose-Response Relationship, DrugDrug CombinationsEnzyme InhibitorsIsoenzymesLysineMaleNitric Oxide4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamideBenzenesulfonamidesCarrageenanCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDrug CombinationsEnzyme InhibitorsIsoenzymesLysineN(6)-(1-iminoethyl)lysineNitric OxideNitric Oxide SynthaseNitric Oxide Synthase Type IINos2 protein, ratProstaglandin-Endoperoxide SynthasesProstaglandinsPyrazolesSulfonamides

Identifiers

PMID15547079
PMCPMC1754842
OpenAlexW2148087534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.